![Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d2c25b15-2f11-4698-a532-bf7c183b6a74/gr1.gif)
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology
![Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins | Cell Death & Differentiation Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins | Cell Death & Differentiation](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41418-020-00654-2/MediaObjects/41418_2020_654_Fig1_HTML.png)
Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins | Cell Death & Differentiation
![Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial - The Lancet Oncology Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f6a15baa-c13a-4d5b-a19c-7f91d6c158f8/gr1.jpg)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial - The Lancet Oncology
![Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study - The Lancet Oncology Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/daf752aa-5364-400e-a9ac-93c62809bf17/gr1.jpg)